Changshan Pharmaceutical announced that the company recently received a notice that enoxaparin sodium injection has obtained a drug registration certificate issued by the Mongolian Drug Administration. The registration number is FR20260911BP09272. The specification is 60 mg/0.6 ml, 2 bottles/box packaging, and the registration certificate is valid until September 11, 2031. This drug can be used to prevent venous thromboembolic diseases, treat deep venous embolism, etc. This certification has had a positive impact on the company's expansion into overseas markets. Currently, the company's overseas sales revenue for heparin formulation products accounts for a low proportion of total revenue, and there is uncertainty about future export sales.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.